FDA converts Novartis' NSCLC drug to a full approval with confirmatory data

Although Novartis discontinued its research into the use of Tabrecta in solid tumors, the FDA on Thursday announced that its accelerated approval would be converted into a full approval for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation leading to mesenchymal-epithelial transition (MET) exon 14 skipping.